Lasa Supergenerics Ltd

Lasa Supergenerics Ltd

$LASAPharmaceuticalsNSEBSE

Lasa Supergenerics Ltd (LASA) last traded at ₹6.82, a market capitalisation of ₹34.2 crore. Over the past 52 weeks the stock has ranged between ₹5.65 and ₹14.1. Lasa Supergenerics Ltd last reported results for the quarter ended Jun 2026, with sales of ₹1.23 crore and net profit of ₹-3.58 crore. Figures are as of 25 Aug 2026 and are not real time.

Lasa Supergenerics Ltd share price and key metrics

Current price
₹6.82
Market cap
₹34.2 cr
Book value
₹9.9
ROE
-19.6%
ROCE
-18.2%
Dividend yield
0.00%
52w high / low
14.1/5.65

Metrics as of 25 Aug 2026. Not real time.

Lasa Supergenerics Ltd quarterly results

In the quarter ended Jun 2026, sales were ₹1.23 cr, down 93.9% from ₹20.01 cr a year earlier. Net profit was ₹-3.58 cr, up 83.0% year on year.

Lasa Supergenerics Ltd consolidated quarterly results, figures in ₹ crore
₹ croreSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales39.3933.0839.1420.013.062.2-0.131.23
Expenses38.632.8135.7320.517.062.951.992.62
Operating profit0.790.273.41-0.5-4-0.75-2.12-1.39
OPM %2.01%0.82%8.71%-2.50%-130.72%-34.09%-113.01%
Other income1.958.91-21.52-20.440.010.02-0.42-0.38
Interest1.240.470.110.030.120.110.130.14
Depreciation2.812.83.91.571.571.571.311.57
Profit before tax-1.315.91-22.12-22.54-5.68-2.41-3.98-3.48
Tax %146.56%7.11%-35.40%-6.30%10.04%5.81%4.77%3.16%
Net profit-3.235.49-14.29-21.12-6.25-2.55-4.16-3.58
EPS (₹)-0.641.10-2.85-4.22-1.25-0.51-0.83-0.71

Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.

Lasa Supergenerics Ltd annual results

Lasa Supergenerics Ltd annual profit and loss, figures in ₹ crore
₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales201137130104142256
Operating profit4716-626-7-8
OPM %24%12%-4.9%2.1%4.4%-29%-130%
Net profit23-5-39-22-15-34-17
EPS (₹)5.60-1.31-7.71-4.34-2.95-6.80-3.30

TTM is the trailing twelve months to the most recent quarter.

Lasa Supergenerics Ltd growth and returns

Compounded Sales Growth
10 Years
%
5 Years
-34%
3 Years
-42%
TTM
-95%
Compounded Profit Growth
10 Years
%
5 Years
%
3 Years
10%
TTM
-547%
Stock Price CAGR
10 Years
%
5 Years
-38%
3 Years
-35%
1 Year
-21%
Return on Equity
10 Years
1%
5 Years
-8%
3 Years
-10%
Last Year
-20%

Lasa Supergenerics Ltd shareholding pattern

Promoters held 53.65% at Mar 2026, broadly unchanged since Mar 2025. FIIs 0.00%.

Lasa Supergenerics Ltd shareholding pattern by quarter, in percent
% heldJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters53.65%53.65%53.65%53.65%53.65%53.65%53.65%53.65%
FIIs0.00%0.01%0.00%0.00%0.47%0.00%0.00%0.00%
Public46.34%46.32%46.35%46.35%45.88%46.35%46.34%46.35%
No. of shareholders27,21727,96827,27227,18828,11528,65628,12027,702

As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.

Lasa Supergenerics Ltd corporate filings

  • Resignation of Mr. Ganesh Potdar executive director as on 25-08-2026Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Lasa Supergenerics Limited has informed the stock exchanges that Mr. Ganesh Potdar has…

    Read the full analysis
  • Integrated filing for Quarter ended June 30, 2026Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Lasa Supergenerics Ltd has submitted its integrated filing for the quarter ended June 30…

    Read the full analysis
  • Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held ....Board Meetinghigh impact
    Filing PDF

    Cruxal's analysis: Lasa Supergenerics Limited reported a net loss of 3.57 crore for the quarter ended June…

    Read the full analysis

This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.

Track Lasa Supergenerics Ltd

Cruxal reads every Lasa Supergenerics Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Cruxal publishes market data and coverage for information only. Nothing here is investment advice.

Lasa Supergenerics Ltd (LASA) Results, Financials & Share Price | Cruxal